Table 3 Best Overall Tumor Response to Second-Line Treatment
Original cohort | Propensity-score matching cohort | |||||
|---|---|---|---|---|---|---|
Afatinib (n = 19) | Chemotherapy (n = 89) | p-value | Afatinib (n = 19) | Chemotherapy (n = 19) | p-value | |
Disease control, n (%) | 16 (84.2) | 41 (46.1) | 0.003* | 16 (84.2) | 8 (42.1) | 0.007* |
Objective response, n (%) | 5 (26.3) | 7 (7.9) | 0.020* | 5 (26.3) | 2 (10.5) | 0.209* |
CR, n (%) | 0 (0) | 0 (0) | .. | 0 (0) | 0 (0) | .. |
PR, n (%) | 5 (26.3) | 7 (7.9) | .. | 5 (26.3) | 2 (10.5) | .. |
SD, n (%) | 11 (57.9) | 34 (38.2) | .. | 11 (57.9) | 6 (31.6) | .. |
PD, n (%) | 2 (10.5) | 43 (48.3) | .. | 2 (10.5) | 7 (36.8) | .. |
NE, n (%) | 1 (5.3) | 5 (5.6) | .. | 1 (5.3) | 2 (10.5) | .. |
Time on first-line treatment, months (95% CI) | 6 (1.2–9.1) | 5.4 (0.9–11.2) | .. | 6 (1.2–9.1) | 3.5 (0.4–13.9) | .. |
PFS, months (95% CI) | 4.7 (0.1–7.5) | 2.6 (0.9–6.7) | .. | 4.7 (0.1–7.5) | 1.9 (0.4–8.4) | .. |
OS, months (95% CI) | 16.0 (6.1–22.0) | 12.3 (6.2–33.9) | .. | 16.0 (6.1–22.0) | 9.9 (6.2–39.4) | .. |